Sarah Hughes

A new AU$481M deal with Everest Medicines brings a promising FSGS drug closer to 1M Asian patients, part of a larger, de-risked global strategy.

Csquare is going public to fund the AI boom, but its S-1 filing reveals a complex picture of soaring revenue, mounting losses, and significant debt.

A new 'Global Lean IT Day' spotlights the immense pressure on under-resourced tech teams. I investigate if this is true advocacy or a savvy market grab.

As remote production booms, a major security flaw has emerged. Backlight's Iconik now integrates Castlabs tech to protect media from the very first frame.

The beloved wildlife warrior is tackling a new habitat: the male bedroom. Is this a genuine wellness push or a masterful marketing ploy for better bedding?

Acurx Pharma's new drug, ibezapolstat, offers a novel weapon against deadly infections like C. diff by sparing good bacteria. Is this the breakthrough we need?

A new AI platform promises to slash drug development red tape. But can it overcome the industry’s deep-rooted challenges of privacy, trust, and integration?

SPC Nickel is betting big on Nunavut's Muskox Intrusion, using advanced tech to hunt for a Norilsk-scale prize. But in the Arctic, the real tests lie beyond the bedrock.

A chronic shortage of poll workers threatens American democracy. Now, a strategic alliance is deploying one of the nation’s most trusted groups—veterans—to fill the gap.

Enterprises have poured billions into data and AI, but many still struggle to turn insights into action. A new suite of tools aims to fix the disconnect.

As the complex Non-QM mortgage market booms, one lender is giving its partners a free AI tool. It’s a glimpse into a future where algorithms decide who gets a loan.

In Pensacola, historic homes are more than architecture; they're a story. But who gets to tell that story, and what happens when heritage meets marketing?

The crypto exchange touts democratized access to elite investments. But beneath the hype of Pre-IPO tokens lies a world of regulatory risk and unclear ownership.

As the Port of Trois-Rivières posts a sharp drop in cargo, its leaders are betting a $312M overhaul will secure its future. But is it a sound investment?

For decades, patients with advanced chondrosarcoma had no options. Now, a new drug's journey to the FDA offers a lifeline and a lesson in medical neglect.

Phase 1 data for Marea Therapeutics’ MAR002 suggests a potential new era for acromegaly treatment, promising better control with far fewer injections.

The 18th Straits Forum promotes 'people-to-people' ties, but Taipei calls it a political ploy. What's at stake for the people caught in between?

SKHTU Exchange touts a localized push for a Malaysian crypto license. But as it courts one of Asia's top regulators, a trail of questionable claims casts a shadow.

Carol Craig, a trailblazing space entrepreneur, just joined the board of an oil company drilling in the Arctic. Is this tech-fueled innovation or a final, desperate fossil fuel gambit?

Hisense's dazzling World Cup pop-up at Hudson Yards offers fans a tech-fueled fantasy. But beneath the surface lies a calculated play for market dominance.